Abstract
Executive Summary
Cancer cells frequently and possibly invariably possess apoptotic defects. In
this context, apoptotic pathways provide exciting molecular targets for new
therapeutic agents to specifically promote apoptosis of cancer cells.
There are today more than 300 apoptopic drugs in active development for the
treatment of cancer, from early preclinical to marketed drugs. In addition,
the accumulated number of ceased drugs over the last three years amount to
another 81 drugs. Apoptosis in Oncology: Drug Pipeline Update lists all drugs
and gives you a progress analysis on each one of them. Identified drugs are
linked to 188 different targets. These targets are further categorized on the
CD-ROM by 52 classifications of molecular function and with pathway referals
to BioCarta, KEGG and NetPath. Read more below on how the Apoptosis in
Oncology: Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
Drug Pipeline Update is delivered to you as a CD-ROM application, which
requires no installation on your computer.
| 
View Cart
